Teng Teng

This publication record appears to combine work from multiple distinct researchers sharing the name Teng Teng, spanning cancer drug discovery (splicing modulators, epigenetic inhibitors, CRISPR screening), aquaculture and toxicology, neuroscience, DNA nanotechnology, and supply-chain management. Within the cancer-focused thread, the work centers on developing and characterizing small-molecule cancer therapies, including inhibitors that target RNA splicing machinery, epigenetic enzymes, and protein degradation pathways, often tested in genetically defined tumor models. Because the topic relevance scores are all listed as zero and the publication venues span highly unrelated fields, prospective students should verify institutional affiliation and specific subfield directly, as this record likely aggregates multiple same-named authors.

Publication output was low or absent in the middle of the decade (2020-2022) but has increased noticeably from 2023 through 2026, suggesting a recent growth phase, though this may reflect multiple contributors under the same name.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026